Alfacidol Soft Capsule 1 Microgram (Alfacalcidol)

Adult dosage

Chronic kidney disease, osteoporosis: Administer 0.5 to 1 ㎍ of alfacalcidol orally once daily. Hypoparathyroidism, other vitamin D metabolism-related diseases: Administer 1 to 4 ㎍ of this medication orally once daily.

Children's dosage

Osteoporosis: Administer 0.01 to 0.03 ㎍ of alfacalcidol orally once daily per kg of body weight. Other conditions: Administer 0.05 to 0.1 ㎍ of this medication orally once daily per kg of body weight.

This medication should not be taken by patients with elevated blood mineral levels, such as hypercalcemia, hyperphosphatemia, or hypermagnesemia. Patients whose calcium and phosphorus product in the blood exceeds a certain level or who are in an alkalosis state should also avoid this medication. Patients with signs of vitamin D toxicity or allergies to any ingredients in this medication should refrain from taking it. During the use of this medication, it is important not to take magnesium-containing agents, vitamin D and its derivatives, calcium-containing preparations, or certain diuretics together. This is because the risk of side effects such as hypercalcemia or hypermagnesemia may increase when taken together. Breastfeeding women should avoid taking this medication as safety has not been established; if necessary, it is recommended to discontinue breastfeeding while using it. Pregnant women or those who may be pregnant should only take this medication after thoroughly consulting with a doctor, as it may be harmful to the fetus. Children, the elderly, and patients taking certain medications should also consult with a professional before taking it and should monitor their serum calcium levels periodically. While taking this medication, various symptoms related to hypercalcemia, such as digestive disorders, neurological abnormalities, heart problems, reduced kidney function, liver function abnormalities, skin rashes, eye issues, etc., may occur. If these symptoms arise, discontinue use immediately and consult a professional. Particularly, patients with kidney stones or sarcoidosis, or those allergic to Yellow No. 5 should use this medication cautiously. While taking this medication, strictly adhere to dosage and administration, adjust calcium intake appropriately, and be aware of the symptoms of hypercalcemia. In case of overdose, discontinue use immediately and seek emergency treatment, and regularly check serum calcium levels to maintain them within the normal range. This medication should be kept out of the reach of children and stored in a cool, dry place, protected from direct sunlight. It is also advisable not to transfer it to other containers to maintain quality.

Serious side effects

• Hives, severe swelling, chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions
• Severe rash with high fever, blisters, skin peeling, pain in mouth/eye mucosa, severe skin adverse reactions
• Shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever
• Yellowing of the skin or eyes, general lethargy, liver abnormalities (jaundice)
• Sudden and severe headache, thunderclap headache

Mild side effects

• Loss of appetite
• nausea
• vomiting
• diarrhea
• constipation
• stomach pain
• discomfort in the upper abdomen
• abdominal bloating
• indigestion
• thirst

This medication is sensitive to light and should be stored in a container that does not allow light to enter. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance

Domestic: Orange oval soft capsule containing a colorless or transparent oily liquid Export: Transparent soft capsule filled with light brown contents

Package unit

Domestic - 30 capsules/bottle, Domestic - 100 capsules/bottle, Domestic - 100 capsules/box [10 capsules/PTP X 10], Export - 10 capsules/bottle, Export - 30 capsules/bottle, Export - 60 capsules/bottle, Export - 100 capsules/bottle